Ways to reduce drug costs in Australia

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Ways to reduce drug costs in Australia

Genéricos/Investigación | Posted 29/07/2016 0 Post your comment

Drug costs in Australia are increasing at an alarming rate. This is driven mainly by expensive biological therapies, antiviral therapies for HIV and hepatitis C and new cancer treatments.

According to researchers from the Royal Brisbane and Women’s Hospital and Calvary Mater Newcastle Hospital, in 2011, New Zealand paid less than half what Australia spent on medications per capita. This has been achieved by having a capped budget and competitive tendering [1]. This is not the first time medicines prices in Australia have been criticized. The Health Forum of Australia (CHF) has claimed that Australians pay AU$3 million more for generics than they would if they bought them in New Zealand or the UK [2].

Just some of the challenges highlighted by Professor Denaro include ‘knowing whether taxpayers are receiving value for money, funding treatments for the expanding ageing population, predicting long-term outcomes and cost-effectiveness for highly expensive medicines with inadequate long-term trial data’. He adds that there are also ‘challenges in justifying extremely costly drugs for a few patients with a rare disease, and finding the funding while not reallocating resources from other areas of health care’.

Some solutions suggested include:
• Use of less costly biosimilars
• Determining value for money with post-marketing surveillance to assess important clinical outcomes
• Waiving assessment fees for evaluation of older drugs where the indication for their use is cost-effective compared to other drugs and where robust evidence for efficacy and safety exists
• Introducing safeguards for patients and taxpayers to guard against trade agreements affecting access to affordable drugs or delaying the availability of generic or biosimilar drugs
• Introducing an electronic national formulary for all Australian hospitals to improve decision-making and allow uniform access to efficacious and cost-effective drugs for all Australians

Drug companies are profit driven, while Australians are looking for the best value for money. A balance must be struck, however, between encouraging innovation and entrepreneurship while still making drugs affordable for the healthcare system.

Australian price cuts make PBS affordable

References
1. Denaro C, Martin J. The challenge of costly drugs. Aust Prescr. 2016;39(3):72-4.
2. GaBI Online - Generics and Biosimilars Initiative. Australians pay too much for generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jul 29]. Available from: www.gabionline.net/Generics/General/Australians-pay-too-much-for-generics

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.